Mouse CXCL9/MIG Recombinant Protein (86-024)

CATALOG NUMBER: 86-024

Tested Applications:
Bioactivity Test, ELISA, Immunogen, SDS-PAGE, WB
Specifications
source-species:
Pichia
Species:
Mouse
source-species:
Pichia
Recombinant Protein Sequence:
Thr 22-Thr 126
Fusion Tag:
C-His
Tested Applications:
Bioactivity Test, ELISA, Immunogen, SDS-PAGE, WB
Application Note:
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity Test
Predicted Molecular Weight:
13.14 kDa
Purity:
≥ 95 % as determined by SDS-PAGE.
Endotoxin:
Please contact us for more information.
physical-state:
Lyophilized
Buffer:
Lyophilized from sterile PBS, pH 7.4
Storage Conditions:
Store at -20°C.Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.
Additional Names:
Mig; Scyb9
Protein Accession Number:
NP_032625.2
Ncbi Gene Id Number:
17329
Background:
Chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (MIG), is a small cytokine belonging to the CXC chemokine family. The function of this chemokine has not been specifically defined; however, it is thought to be involved in T cell trafficking. CXCL9/MIG functions as one of the three ligands of chemokine receptor CXCR3 which is a G protein-coupled receptor found predominantly on T cells. CXCL9/MIG, together with CXCL10 and CXCL11, may activate CXCR3 by binding to it. CXCL9 serves as a cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. It has been observed that tumour endothelial cells secrete high levels of CXCL9 in all, and CXCL10 in most melanoma metastases. Experiment data represent novel mechanisms by which tumour cells in melanoma metastases might use the chemokine-expressing endothelium to leave the tumour and eventually to form additional metastases at distinct sites. Experiment results also improved that CXCL9/MIG plays an important role in CD4+ T lymphocyte recruitment and development of CAV, MOMA-2+ macrophages are the predominant recipient-derived source of CXCL9/MIG, and recipient CD4 lymphocytes are necessary for sustained CXCL9/MIG production and CAV development in this model. Neutralization of the chemokine CXCL9/MIG may have therapeutic potential for the treatment of chronic rejection after heart transplantation.

FOR RESEARCH USE ONLY

For additional information, visit ProSci’s Terms & Conditions Page.

Disclaimer:
Products are intended for laboratory research purposes only and should be used by qualified personnel only. They are not intended for use in humans. ProSci is not liable for damages or injuries resulting from receipt and/or use of ProSci materials. Please refer to the Material Safety Data Sheet (MSDS) for safe storage, handling, and use procedures.

CATALOG NUMBER:

86-024

List Size:
0.01 mg, 0.05 mg

List Price:

Price range: $140.00 through $350.00

Shipping Info
Customize your order
Custom Antibody Services

New & Featured Products

CATALOG NUMBER: PM-7369-HRP

CATALOG NUMBER: PM-7369-biotin

CATALOG NUMBER: PM-7369